Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Would be nice to see Egrifta mentioned in this article

<< Previous

Bullboard Posts

Next >>

Post by SPCEO1on Feb 29, 2024 12:34pm

113 Views

Post# 35906860

Would be nice to see Egrifta mentioned in this article

In the post-Viking environment and with XBI on a big run, it would no doubt propel the THTX stock price quite a bit.

https://www.msn.com/en-us/health/other/weight-loss-drugs-have-one-big-problem-these-drugmakers-are-taking-it-on/ar-BB1iLJuB?ocid=socialshare

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec